Table 3.
Statistical analyses for treatment effect in relation to personality disorder and treatment condition
| Outcome measure | SPSP | CBT | PD*condition, difference (s.e.) |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No personality disorder, mean (s.d.) |
N | Effect size d (95% CI) | Comorbid personality disorder, mean (s.d.) |
N | Effect size d (95% CI) | No personality disorder, mean (s.d.) | N | Effect size d (95% CI) | Comorbid personality disorder, mean (s.d.) | N | Effect size d (95% CI) | ||
| HRSD | |||||||||||||
| Baseline | 21.25 (4.32) | 36 | 23.32 (5.31) | 68 | 22.37 (4.41) | 27 | 23.06 (5.27) | 65 | 0.74 (2.15) | ||||
| Week 10 | 13.74 (6.07) | 32 | 19.63 (8.19) | 62 | 14.85 (8.11) | 20 | 16.69 (8.07) | 55 | −0.18 (2.32) | ||||
| Week 22 | 13.42 (8.03) | 36 | 1.58 (1.05–2.11) | 16.57 (8.70) | 61 | 1.43 (1.03–1.83) | 12.87 (7,56) | 23 | 1.90 (1.21–2.60) | 14.65(9.24) | 52 | 1.22 (0.80–1.64) | −0.23 (2.25) |
| Week 52 | 10.36 (5.71) | 28 | 2.53 (1.83–3.23) | 16.56 (9.25) | 50 | 1.32 (0.88–1.75) | 10.42 (7.63) | 19 | 2.28 (1.47–3.10) | 12.60 (9,78) | 48 | 1.64 (1.17–2.10) | −3.02 (2.42) |
| IDS | |||||||||||||
| Baseline | 36.45 (9.51) | 35 | 44.61 (11.02) | 61 | 39.69 (7.47) | 26 | 42.50 (8.43) | 56 | 1.43 (2.42) | ||||
| Week 10 | 29.54 (14.33) | 29 | 37.15 (13.19) | 54 | 25.35 (11.39) | 20 | 33.71 (16.32) | 48 | −4.73 (3.62) | ||||
| Week 22 | 20.37 (12.67) | 31 | 1.94 (1.33–2.56) | 33.06 (16.23) | 49 | 1.37 (0.91–1.82) | 25.29 (13.57) | 19 | 1.52 (0.79–2.24) | 31.10 (16.76) | 42 | 1.25 (0.76–1.73) | −1.68 (3.69) |
| Week 52 | 16.43 (10.69) | 24 | 3.42 (2.51–4.33) | 31.00 (14.95) | 29 | 1.27 (0.68–1.85) | 16.48 (14.28) | 15 | 2.86 (1.84–3.88) | 23.48 (17.24) | 35 | 1.79 (1.21–2.37) | 3.51 (4.20) |
| OQ interpersonal relations | |||||||||||||
| Baseline | 16.20 (5.85) | 20 | 23.00 (5.34) | 48 | 16.63 (6.66) | 19 | 20.81 (4.76) | 47 | 0.63 (1.86) | ||||
| Week 10 | 15.40 (8.56) | 97 | 20.37 (6.62) | 47 | 12.81 (6.78) | 17 | 18.95 (7.58) | 48 | −2.71 (2.13) | ||||
| Week 22 | 12.45 (6.67) | 22 | 0.91 (0.16–1.66)) | 19.14 (7.56) | 35 | 0.78 (0.24–1.33) | 11.15 (4.95) | 13 | 1.03 (0.14–1.92) | 17.85 (6.03) | 28 | 0.57 (0.00–1.15) | −1.41 (2.34) |
| Week 52 | 11.41 (6.24) | 12 | 0.90 (−0.13–1.93) | 17.73 (6.84) | 15 | 1.30 (0.45–2.15) | 10,82 (7.32) | 11 | 0.78 (−0.13–1.69) | 15.81 (8.33) | 21 | 1.43 (0.68–2.18) | −2.13 (2.89) |
| OQ social role functioning | |||||||||||||
| Baseline | 13.69 (4.15) | 26 | 17.28 (5.19) | 47 | 14.73 (6.36) | 22 | 16.63 (5.27) | 49 | 0.84 (1.54) | ||||
| Week 10 | 12.12 (4.47) | 26 | 14.86 (4.95) | 49 | 10.74 (4.11) | 48 | 14.19 (6.02) | 97 | −2.91 (1.79) | ||||
| Week 22 | 11.15 (4.84) | 26 | 1.11 (0.44–1.77) | 13.53 (5.46) | 36 | 0.89 (0.38–1.41) | 11.13 (5.61) | 16 | 0.78 (0.01–1.54) | 13.23 (6.23) | 30 | 0.78 (0.19–1.37) | −0.28 (1.90) |
| Week 52 | 12.64 (4.46) | 11 | 0.35 (−0.64–1.34) | 14.00 (5.75) | 16 | 0.91 (0.15–1.66) | 8.23 (5.69) | 13 | 0.91 (0.03–1.79) | 11.65 (5.90) | 23 | 0.64 (0.00–1.27) | −4.07 (2.48) |
| EQ-5D | |||||||||||||
| Baseline | 0.41 (0.30) | 31 | 0.35 (0.31) | 62 | 0.48 (0.30) | 25 | 0.38 (0.31) | 55 | 0.006 (0.08) | ||||
| Week 10 | 0.56 (0.29) | 29 | 0.43 (0.28) | 53 | 0.72 (0.25) | 20 | 0.52 (0.34) | 49 | −0.05 (0.09) | ||||
| Week 22 | 0.73 (0.28) | 26 | 1.32 (0.70–1.95) | 0.55 (0.35) | 43 | 0.97 (0.52–1.43) | 0.67 (0.33) | 19 | 1.00 (0.31–1.69) | 0.59 (0.32) | 32 | 1.01 (0.48–1.55) | −0.15 (0.09) |
| Week 52 | 0.72 (0.25) | 14 | 2.93 (1.73–4.14) | 0.63 (0.35) | 16 | 1.42 (0.65–2.20) | 0.73 (0.36) | 14 | 1.19 (0.36–2.02) | 0.64 (0.33) | 26 | 0.83 (0.25–1.41) | −0.02 (0.12) |
SPSP, short-term psychodynamic supportive psychotherapy; CBT, cognitive–behavioural therapy; EQ-5D, EuroQol-5D; HRSD, Hamilton Rating Scale for Depression; IDS, Inventory of Depressive Symptomatology; OQ, Outcome Questionnaire; s.d., standard deviation; s.e., standard error; CI, confidence interval.
*
P < 0.05.